Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target.
肝激素與 MASLD:GLP1-Ras-FGF21-Fetuin-A 交互作用作為治療靶點。
Int J Mol Sci 2024-10-16
Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum.
前沿生物治療法及先進給藥策略在代謝功能障礙相關脂肪肝疾病範疇的治療。
J Control Release 2025-02-09
Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options.
代謝功能障礙相關脂肪肝病及相關疾病的藥物治療:目前及新興的治療選擇。
Pharmacol Rev 2025-03-27
Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure.
代謝功能障礙相關脂肪性肝病(Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD)對心血管結構、功能及心臟衰竭風險的影響
Can J Cardiol 2025-04-21
Complexity of Metabolic dysfunction-associated steatotic liver disease (MASLD): State of art review.
代謝功能異常相關脂肪性肝病(MASLD)的複雜性:現況綜述
J Chin Med Assoc 2025-06-13